Quick Facts
Plain-English Summary
Kisspeptin is an endogenous peptide encoded by the KISS1 gene — the same gene first discovered in 1996 as a suppressor of melanoma metastasis, which is how it acquired the name "metastin." Its role in reproductive endocrinology was not recognised until 2003, when GPR54 knockout mice were found to be infertile despite otherwise normal development, implicating KISS1 signalling as an essential upstream gate of the reproductive axis. That discovery reshaped neuroendocrinology: the reproductive cascade does not begin with GnRH, as was long assumed, but further upstream with kisspeptin neurons in the hypothalamus.
The physiological cascade runs as follows: kisspeptin neurons in the arcuate and anteroventral periventricular nuclei release kisspeptin, which acts on GPR54 receptors on GnRH neurons to drive pulsatile GnRH secretion into the portal circulation. GnRH then stimulates pituitary gonadotrophs to release LH and FSH, which in turn drive gonadal steroidogenesis — testosterone in men, estrogen and progesterone in women. Kisspeptin is therefore not a peripheral hormone; it is the hypothalamic master switch for the entire reproductive hormone axis.
In the reproductive medicine context, kisspeptin is being studied for two primary indications: functional hypothalamic amenorrhea (FHA) — a stress- or energy-deficit-driven shutdown of the GnRH pulse generator common in female athletes and restrictive eaters — and as a potential physiological alternative to hCG as an IVF ovulation trigger. Human trial data by Dhillo, Jayasena, and colleagues at Imperial College London has established that IV kisspeptin infusion reliably stimulates LH and testosterone secretion in healthy men and restores pulsatile LH secretion in women with FHA. This represents a level of reproducible human neuroendocrine data that is uncommon in the peptide research space.
Kisspeptin stands out among research peptides for having multiple independent groups produce consistent, peer-reviewed human trial data. The reproductive endocrinology evidence base — while still pre-approval — is significantly stronger than most compounds in this category.
The KISS1 oncology angle is a separate and active research thread. KISS1 expression is inversely correlated with metastatic potential in melanoma, thyroid carcinoma, and several epithelial cancers. Tumours that lose KISS1 expression show enhanced invasiveness; forced re-expression suppresses metastatic spread in animal models. Whether pharmacological kisspeptin administration influences cancer biology in humans is not established, but KISS1 is considered a relevant tumour suppressor gene across multiple cancer types.
The community narrative around kisspeptin as a testosterone booster significantly overstates the evidence. Published LH and testosterone responses are acute, transient, and observed under IV infusion conditions in controlled research settings — not from subcutaneous self-administration protocols common in the peptide community.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| GPR54 knockout mice | Complete reproductive failure: arrested puberty, absent LH pulsatility, and infertility despite intact gonadal architecture. Phenotype fully rescued by exogenous kisspeptin administration. Established kisspeptin as non-redundant for reproductive function. Seminara et al. NEJM 2003 ↗ | Preclinical |
| Rat hypothalamic infusion | Dose-dependent LH surges following central or peripheral kisspeptin injection. Robust response across species (rat, sheep, monkey). Effect blocked by GnRH antagonists, confirming mechanism is GnRH-dependent. Irwig et al. 2004 ↗ | Preclinical |
| Female rat — negative energy balance | Fasting-induced suppression of LH pulsatility is associated with reduced arcuate kisspeptin neuron activity. Exogenous kisspeptin partially restores LH pulse frequency in food-restricted animals — supporting the hypothalamic amenorrhea research rationale. | Preclinical |
| Melanoma — KISS1 re-expression | Forced KISS1 re-expression in C8161 human melanoma cells (naturally KISS1-negative) dramatically reduced pulmonary metastasis in nude mouse xenograft models with no effect on primary tumour growth, demonstrating metastasis-specific suppression. Lee & Bhatt 1996 ↗ | Preclinical |
| Breast cancer — KISS1 expression | KISS1 mRNA expression inversely correlates with metastatic potential across breast cancer cell lines. Low-KISS1 lines show enhanced invasion and extravasation; high-KISS1 lines are significantly less metastatic in animal models. | Preclinical |
| Thyroid carcinoma | KISS1 expression is markedly reduced in papillary and follicular thyroid carcinomas with lymph node involvement compared with node-negative tumours, consistent with a metastasis suppressor role across epithelial cancers. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Dhillo WS et al. 2005 — First Human Trial | 6 healthy men, single IV bolus kisspeptin-54 (0.24–9.6 nmol/kg) | — | Peer-Reviewed |
| Jayasena CN et al. — Hypothalamic Amenorrhea | Women with functional hypothalamic amenorrhea (FHA), IV kisspeptin vs. saline | — | Peer-Reviewed |
| Pineda R et al. — IVF Ovulation Trigger | Women undergoing IVF with risk of ovarian hyperstimulation syndrome (OHSS) | — | Investigational |
| Subcutaneous kisspeptin — self-admin models | Research volunteers, SC dosing protocols | — | Limited |
Kisspeptin has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
All published IV kisspeptin studies report no serious adverse events. Short-term hormonal responses (LH, FSH surges) were transient and resolved without intervention. The peptide is endogenous, which limits concerns about foreign molecule toxicity at physiological-range doses.
Exogenous kisspeptin overrides endogenous GnRH pulse regulation. Chronic or high-dose administration risks pituitary desensitisation through GnRH receptor downregulation — the same mechanism by which GnRH agonists used in prostate cancer treatment suppress testosterone. Continuous-infusion kisspeptin paradoxically suppresses LH in animal studies.
- Transient facial flushing (IV route)
- Mild headache or lightheadedness
- Injection site irritation (SC route)
- Temporary libido fluctuation
- No pharmacovigilance database exists for non-clinical use
- Hormone-sensitive malignancies (prostate, breast, ovarian)
- Established pregnancy
- Pituitary adenoma or hypothalamic pathology
- Active GnRH agonist or antagonist therapy
- Children and adolescents (active puberty axis)
- Polycystic ovary syndrome (PCOS) — LH excess risk
Kisspeptin is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Kisspeptin for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
What distinguishes kisspeptin from almost everything else in this space is that the human data isn't from a single lab with a publication bias problem — Dhillo's group at Imperial, the Madrid reproductive neuroendocrinology group, and several North American IVF researchers have all independently replicated the LH response. The signal is real. The question the community consistently skips is: what does a 28-minute half-life and IV administration requirement mean for self-injection protocols? The pharmacokinetics are brutal subcutaneously — you're not getting the portal-vein drug concentrations that drive the hypothalamic response.
Exactly this. The Jayasena 2014 tachyphylaxis paper is the one everyone should read before touching this compound. Chronic SC kisspeptin actually suppressed LH in some subjects — the mechanism being exactly what you'd expect from a GnRH-axis agonist given continuously: receptor downregulation. It's the same pharmacology that makes Lupron (leuprolide) an anti-androgen despite being a GnRH agonist. Pulsatile delivery matters enormously and SC self-injection doesn't replicate that.
The metastasis suppressor angle gets almost no attention in the biohacking community but is arguably the most scientifically interesting part of kisspeptin's profile. KISS1 behaves like a context-dependent tumour suppressor — it doesn't affect primary tumour growth but dramatically reduces metastatic efficiency across melanoma, breast, and thyroid models. The mechanism seems to involve downregulation of MMP activity and reduced extravasation through the vascular endothelium. The unanswered question is whether exogenous kisspeptin administration actually raises tumour KISS1 expression or affects KISS1-negative tumour cells — probably not, since the gene's expression is a cell-intrinsic property.
As someone who dealt with hypothalamic amenorrhea for three years, the research trajectory on kisspeptin for FHA is genuinely exciting — not as self-medication, but as an indication that may eventually have a proper treatment pathway. The Jayasena FHA studies are one of the few places in reproductive medicine where a physiologically rational intervention (stimulating the suppressed GnRH pulse generator rather than bypassing it with exogenous hormones) has actually shown clinical signal. The IVF ovulation trigger work is also credible — it avoids the OHSS risk that comes with hCG. These are legitimate medical applications that deserve the research investment they're getting.
Well put. The FHA and IVF trigger applications are the strongest arguments for continued clinical development. The problem is that the community has latched onto it as a testosterone optimisation tool for healthy men — which is a much weaker indication where the risk-benefit calculus looks completely different. Healthy men with intact LH pulsatility don't need kisspeptin; men with secondary hypogonadism might, but that's a clinical conversation, not a peptide-vendor conversation.
From a translational standpoint, kisspeptin faces a route-of-administration problem that's holding back the clinical pipeline. The half-life is too short for subcutaneous dosing to produce meaningful portal concentrations, and IV infusion isn't scalable for outpatient therapeutic use. Kisspeptin analogues with extended half-life or oral bioavailability are the real prize — TAK-448 and other GPR54 agonist programmes are working on exactly this. The question isn't whether kisspeptin biology is real; it's whether a stable, orally bioavailable agonist can be delivered to a broad patient population. That's where the regulatory and commercial story actually leads.